BNTC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

-0.228

-31.06%

-0.240

-0%

-0.315

-25%

Estimates Revision

The market is revising No Change the revenue expectations for Benitec Biopharma Inc. (BNTC) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.50%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-42.91%

In Past 3 Month

Stock Price

Go Down

-12.50%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 26.60 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.180

Low

20.00

Averages

26.60

High

32.00

Current: 12.180

Low

20.00

Averages

26.60

High

32.00

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$35 -> $32

2025-11-24

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$35 -> $32

2025-11-24

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Benitec Biopharma to $32 from $35 and keeps a Buy rating on the shares. The firm cites the completed equity financing for the target cut.

H.C. Wainwright

Buy

maintain

$28 -> $35

2025-11-04

Reason

H.C. Wainwright

Price Target

$28 -> $35

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Benitec Biopharma to $35 from $28 and keeps a Buy rating on the shares. The company reported "highly positive" interim data reported from the first six patients to receive BB-301, the analyst tells investors in a research note. The firm says all six patients in the ongoing Phase 1b/2a trial met the formal statistical criteria for positive response in the proprietary oculopharyngeal muscular dystrophy responder analysis. H.C. Wainwright increased BB-301's probability of approval to 45% from 40%.

Citizens JMP

Outperform

maintain

$20 -> $22

2025-11-04

Reason

Citizens JMP

Price Target

$20 -> $22

2025-11-04

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Benitec Biopharma to $22 from $20 and keeps an Outperform rating on the shares. Benitec presented a 100% response rate for the BB-301 Phase 1b/2a study at the low dose and debuted a composite primary endpoint that sets an easily achievable bar for FDA approval, the analyst tells investors in a research note. The firm continues to be encouraged by the efficacy of BB-301 with several measures showing improvements as the patient number grows to six from three.

Oppenheimer

Andreas Argyrides

Outperform

downgrade

$35 -> $29

2025-09-16

Reason

Oppenheimer

Andreas Argyrides

Price Target

$35 -> $29

2025-09-16

downgrade

Outperform

Reason

Oppenheimer analyst Andreas Argyrides lowered the firm's price target on Benitec Biopharma to $29 from $35 and keeps an Outperform rating on the shares. Since the last corporate update in July, Benitec remains on track to present full data from the Phase 1b/2a clinical study of lead candidate BB-301 in OPMD in October including all six patients in Cohort 1. Based on durable and clinically meaningful improvements in dysphagia seen in the twelve-month data from Cohort 1 presented at the 2025 MDA conference in March, Oppenheimer expects to see continued benefit. Importantly, these data help to inform regulatory discussions whereby Benitec could advance to a registrational trial with a limited number of additional patients at the current dose based on precedent set by other rare disease companies. The firm continues to view Benitec's "silence and replace" DNA-directed RNA interference platform as differentiated, disease-modifying approach to treating OPMD.

TD Cowen

initiated

2025-07-07

Reason

TD Cowen

Price Target

2025-07-07

initiated

Reason

TD Cowen initiated coverage of Benitec Biopharma with a Buy rating and no price target. The company's DNA-directed 'silence and replace' platform combines RNAi silencing sequences with replacement genes, the analyst tells investors in a research note. The firm believes Benitec's lead asset BB-301 for oculopharyngeal muscular dystrophy showed "compelling" Phase 1/2 clinical data, with improving subjective and objective dysphagia measures in three patients.

JMP Securities

Silvan Tuerkcan

Buy

Maintains

$18 → $20

2025-04-10

Reason

JMP Securities

Silvan Tuerkcan

Price Target

$18 → $20

2025-04-10

Maintains

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Benitec Biopharma Inc (BNTC.O) is -10.54, compared to its 5-year average forward P/E of -3.01. For a more detailed relative valuation and DCF analysis to assess Benitec Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.01

Current PE

-10.54

Overvalued PE

0.05

Undervalued PE

-6.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.53

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.93

Undervalued EV/EBITDA

-1.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

160.01

Current PS

0.00

Overvalued PS

557.70

Undervalued PS

-237.69

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 599.83% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BNTC News & Events

Events Timeline

No data

News

6.5

12-05NASDAQ.COM

Wall Street Analysts Forecast an 87.48% Increase for Benitec Biopharma (BNTC): Key Insights to Consider

8.5

11-06Newsfilter

Benitec Biopharma Inc. Reveals Pricing for $100 Million Common Stock Sale

4.0

11-04Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for Benitec Biopharma and Increases Price Target to $35

People Also Watch

Frequently Asked Questions

What is Benitec Biopharma Inc (BNTC) stock price today?

The current price of BNTC is 12.18 USD — it has increased 1.67 % in the last trading day.

What is Benitec Biopharma Inc (BNTC)'s business?

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

What is the price predicton of BNTC Stock?

What is Benitec Biopharma Inc (BNTC)'s revenue for the last quarter?

Benitec Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Benitec Biopharma Inc (BNTC)'s earnings per share (EPS) for the last quarter?

Benitec Biopharma Inc. EPS for the last quarter amounts to -0.22 USD, decreased -54.17 % YoY.

What changes have occurred in the market's expectations for Benitec Biopharma Inc (BNTC)'s fundamentals?

How many employees does Benitec Biopharma Inc (BNTC). have?

Benitec Biopharma Inc (BNTC) has 19 emplpoyees as of December 16 2025.

What is Benitec Biopharma Inc (BNTC) market cap?

Today BNTC has the market capitalization of 412.44M USD.